Biothera presents new Impirme PGG data at SITC meeting

Biothera Pharmaceuticals recently presented new Phase 2 Imprime PGG preclinical data that will corroborate the drug’s ability to produce coordinated innate and adaptive immune responses that could increase the effectiveness of other checkpoint inhibitor therapies.
The Imprime PGG data was presented at the Society for Immunotherapy of Cancer’s (SITC) annual meeting in the form of three poster presentations. This year’s SITC meeting was held Nov.11-13 in National Harbor, Maryland.
“The data presented at SITC further elucidate the ability of Imprime PGG to trigger the changes across the immune system that enable a coordinated, anti-cancer immune response,” Biothera Chief Scientific Officer and Senior Vice President of Research Jeremy Graff said. “Importantly, we can show now these changes at the tumor site using the same technology to be used in our upcoming clinical trials.”
New discoveries in multiple in vivo preclinical models validate prior in vitro research proving that the use of Imprime PGG coordinates the innate immune effector cells and the adaptive immune system, which work to further progress the expansion of the cytotoxic T cell and its ability to produce anti-tumor cytokines.